Abbott Laboratories ( ($ABT) ) has released its Q4 earnings. Here is a breakdown of the information Abbott Laboratories ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...

For full-year 2025, the company forecast organic sales growth between 7.5% and 8.5% as well as adjusted earnings per share in the range of $5.05 and $5.25. Analysts polled by FactSet expect $42 ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year that was below market expectations.The stock was down 0.2% Wednesday while ...

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

Abbott Laboratories (ABT) reports robust sales growth and improved margins, setting the stage for continued success in 2025 ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

A high throughput, highly automated test system for blood screening ... and documenting for every run. ABBOTT PRISM is designed to increase lab efficiency. It reduces manual steps and checks ...

The outlook and technical action suggest Abbott Laboratories (NYSE ... in below consensus partly because of weakness in COVID-19 testing, but organic growth is double-digit, and all segments ...

Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...